<table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col></col>
<col></col>
<tbody>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="bold">Inhibitors of CYP3A4 and CYP2D6</content>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>
<content stylecode="italics">Clinical</content>
</paragraph>
<content stylecode="italics">Impact:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>The concomitant use of Oxycodone Hydrochloride Capsules and CYP3A4 inhibitors can increase the plasma concentration of oxycodone, resulting in increased or prolonged opioid effects. These effects could be more pronounced with concomitant use of Oxycodone Hydrochloride Capsules and CYP2D6 and CYP3A4 inhibitors, particularly when an inhibitor is added after a stable dose of Oxycodone Hydrochloride Capsules is achieved <content stylecode="italics">[see Warnings and Precautions (</content>
<content stylecode="italics">
<linkhtml href="#final.docx#Risks_Concomitant_Use_Discontinue_P450">5.4</linkhtml>
</content>
<content stylecode="italics">)</content>
<content stylecode="italics">]</content>.</paragraph> After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the oxycodone plasma concentration will decrease <content stylecode="italics">[see Clinical Pharmacology (</content>
<content stylecode="italics">
<linkhtml href="#final.docx#Pharmacokinetics">12.3</linkhtml>
</content>
<content stylecode="italics">)]</content>, resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to oxycodone.</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">If concomitant use is necessary, consider dosage reduction of Oxycodone Hydrochloride Capsules until stable drug effects are achieved.<paragraph>Monitor patients for respiratory depression and sedation at frequent intervals.</paragraph> If a CYP3A4 inhibitor is discontinued, consider increasing the Oxycodone Hydrochloride Capsules dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal.</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="italics">Examples</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">Macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g. ketoconazole), protease inhibitors (e.g., ritonavir)</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="bold">CYP3A4 Inducers</content>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="italics">Clinical</content>
</paragraph>
<content stylecode="italics">Impact:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">The concomitant use of Oxycodone Hydrochloride Capsules and CYP3A4 inducers can decrease the plasma concentration of oxycodone <content stylecode="italics">[see Clinical Pharmacology (</content>
<content stylecode="italics">
<linkhtml href="#final.docx#Pharmacokinetics">12.3</linkhtml>
</content>
<content stylecode="italics">)</content>
<content stylecode="italics">]</content>, resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to oxycodone <content stylecode="italics">[see Warnings and Precautions (</content>
<content stylecode="italics">
<linkhtml href="#final.docx#Risks_Concomitant_Use_Discontinue_P450">5.4</linkhtml>
</content>
<content stylecode="italics">)</content>
<content stylecode="italics">]</content>.<br/> After stopping a CYP3A4 inducer, as the effects of the inducer decline, the oxycodone plasma concentration will increase <content stylecode="italics">[see Clinical Pharmacology (</content>
<content stylecode="italics">
<linkhtml href="#final.docx#Pharmacokinetics">12.3</linkhtml>
</content>
<content stylecode="italics">)]</content>, which could increase or prolong both the therapeutic effects and adverse reactions, and may cause serious respiratory depression.</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>If concomitant use is necessary, consider increasing the Oxycodone Hydrochloride Capsule dosage until stable drug effects are achieved.</paragraph> Monitor for signs of opioid withdrawal. If a CYP3A4 inducer is discontinued, consider Oxycodone Hydrochloride Capsule dosage reduction and monitor for signs of respiratory depression. </td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="italics">Examples</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">Rifampin, carbamazepine, phenytoin</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="bold">Benzodiazepines and other Central Nervous System (CNS) Depressants</content>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="italics">Clinical</content>
<br/>
<content stylecode="italics">Impact:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants including alcohol, increases the risk of respiratory depression, profound sedation, coma, and death. </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="italics">
<content stylecode="italics">Intervention:</content>
</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients closely for signs of respiratory depression and sedation <content stylecode="italics">[see Warnings and Precautions (</content>
<content stylecode="italics">
<linkhtml href="#final.docx#Risks_Concomitant_Benzodiazepines_Other">5.5</linkhtml>
</content>
<content stylecode="italics">)]</content>.</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="italics">Examples</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="bold">Serotonergic Drugs</content>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="italics">Clinical</content>
<br/>
<content stylecode="italics">Impact:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin. </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Discontinue Oxycodone Hydrochloride Capsules if serotonin syndrome is suspected.</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="italics">Examples</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue). </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="bold">Monoamine Oxidase Inhibitors (MAOIs)</content>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="italics">Clinical</content>
</paragraph>
<content stylecode="italics">Impact:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>MAOI interactions with opioids may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma)</paragraph>
<content stylecode="italics">[see Warnings and Precautions (</content>
<content stylecode="italics">
<linkhtml href="#final.docx#Life_Threatening_Respiratory_Depression">5.2</linkhtml>
</content>
<content stylecode="italics">)].</content> </td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>The use of Oxycodone Capsules is not recommended for patients taking MAOIs or within 14 days of stopping such treatment.</paragraph> If urgent use of an opioid is necessary, use test doses and frequent titration of small doses to treat pain while closely monitoring blood pressure and signs and symptoms of CNS and respiratory depression.</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="italics">Examples</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">phenelzine, tranylcypromine, linezolid </td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="bold">Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics</content>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     "> <paragraph>
<content stylecode="italics">Clinical</content>
</paragraph>
<content stylecode="italics">Impact:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>May reduce the analgesic effect of Oxycodone Hydrochloride Capsules and/or precipitate withdrawal symptoms. </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">Avoid concomitant use. </td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="italics">Examples</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">butorphanol, nalbuphine, pentazocine, buprenorphine </td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="bold">Muscle Relaxants</content>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="italics">Clinical</content>
<br/>
<content stylecode="italics">Impact:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Oxycodone may enhance the neuromuscular blocking action ofskeletal muscle relaxants and produce an increased degree of respiratory depression.  </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Monitor patients for signs of respiratory depression that may be greater than otherwise expected and decrease the dosage of Oxycodone Hydrochloride Capsules and/or the muscle relaxant as necessary. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="bold">Diuretics</content>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="italics">Clinical</content>
<br/>
<content stylecode="italics">Impact:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Monitor patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed. </paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="bold">Anticholinergic Drugs</content>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="italics">Clinical</content>
<br/>
<content stylecode="italics">Impact:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. </paragraph>
</td>
</tr>
<tr>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="     Botrule          Toprule         Lrule          Rrule     ">
<paragraph>Monitor patients for signs of urinary retention or reduced gastric motility when Oxycodone Hydrochloride Capsules is used concomitantly with anticholinergic drugs. </paragraph>
</td>
</tr>
</tbody>
</table>